INLIF (NASDAQ:INLF) & Sanara MedTech (NASDAQ:SMTI) Head-To-Head Analysis

Sanara MedTech (NASDAQ:SMTI) and INLIF (NASDAQ:INLF) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Institutional and Insider Ownership

8.1% of Sanara MedTech shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Sanara MedTech has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, INLIF has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.

Profitability

This table compares Sanara MedTech and INLIF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
INLIF	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings for Sanara MedTech and INLIF, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	2	0	2	0	2.00
INLIF	1	0	0	0	1.00

Sanara MedTech currently has a consensus price target of $34.00, suggesting a potential upside of 52.09%. Given Sanara MedTech’s stronger consensus rating and higher probable upside, analysts plainly believe Sanara MedTech is more favorable than INLIF.

Earnings & Valuation

This table compares Sanara MedTech and INLIF”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$107.48 million	1.91	-$37.56 million	($3.77)	-5.93
INLIF	$18.41 million	2.63	-$5.45 million	N/A	N/A

INLIF has lower revenue, but higher earnings than Sanara MedTech.

Summary

Sanara MedTech beats INLIF on 7 of the 12 factors compared between the two stocks.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

About INLIF

INLIF Ltd. is a holding company, which engages in the development of injection molding machine-dedicated manipulator arms. Its products include: Three-axis robot, Five-axis robot and bull head type manipulator. The company was founded on January 4, 2023 and is headquartered in Quanzhou, China.